公开(公告)号：US20210379055A1

公开(公告)日：2021-12-09

申请号：US16962941

申请日：2019-01-17

申请人： Aurigene Discovery Technologies Limited

发明人： Dinesh Chikkanna ,  Vinayak V. Khairnar ,  Muralidhara Ramachandra ,  Leena Khare Satyam

IPC分类号： A61K31/496 ,  A61K45/06 ,  C07D295/215 ,  C07D205/04 ,  C07D231/56 ,  C07D211/58 ,  C07D333/28 ,  C07C275/26 ,  C07C311/11 ,  C07D211/72 ,  C07D471/08 ,  C07D401/04 ,  C07D207/16 ,  C07C237/24 ,  C07D261/04 ,  A61P35/00 ,  A61K31/495 ,  A61K31/17 ,  A61K31/4468 ,  A61K31/439 ,  A61K31/454

摘要： The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.

公开(公告)号：US11365205B2

公开(公告)日：2022-06-21

申请号：US16982996

申请日：2019-03-20

申请人： Aurigene Discovery Technologies Limited

发明人： Dinesh Chikkanna ,  Sunil Kumar Panigrahi ,  Srinivasa Raju Sammeta ,  Wohlfahrt Gerd ,  Myllymaki Mikko

IPC分类号： C07D401/14 ,  A61K31/4725 ,  C07D498/08 ,  A61P35/00 ,  C07D401/06 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

摘要： The present invention relates to the derivatives of compound of formula (I) and pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and use thereof as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions where PRMT5 inhibition is desired, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.

公开(公告)号：US11542275B2

公开(公告)日：2023-01-03

申请号：US16982800

申请日：2019-03-20

申请人： Aurigene Discovery Technologies Limited

发明人： Dinesh Chikkanna ,  Sunil Kumar Panigrahi ,  Srinivasa Raju Sammeta

IPC分类号： C07D498/08 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/08 ,  C07D487/04 ,  C07D491/107 ,  C07D493/08 ,  C07D495/04

摘要： The present invention relates to substituted imidazolidin-2-one derivatives of formula (I) or pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and utility as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions and disorders mediated by PRMT5, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.